Trial Profile
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Everolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Sep 2011 Planned End Date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 30 Jun 2010 New trial record